Explore

Ventura County Star, CamarilloVentura County Star, Camarillo
Medications for weight loss — a GLP-1 update | Dr. Loh

Medications for weight loss — a GLP-1 update | Dr. Loh

Given all the press and popularity of the GLP-1 receptor agonists, it may be good time for a review of where we are with this class of medications.
Rapid ReadRapid Read
GLP-1 Drug Discontinuation Linked to Increased Cardiovascular Risk in Type 2 Diabetes Patients

GLP-1 Drug Discontinuation Linked to Increased Cardiovascular Risk in Type 2 Diabetes Patients

A three-year follow-up study conducted by researchers at Washington University in St. Louis School of Medicine, published in the international journal BMJ Medicine, indicates that discontinuing GLP-1-based obesity and diabetes treatments significantly increases the risk of heart attack and stroke. The study, which involved approximately 333,000 patients with type 2 diabetes, found that those who stopped GLP-1 treatment experienced a rapid loss of the cardiovascular protection effects provided by the drugs. Patients who ceased GLP-1 treatment for two years had a 22% higher risk of major cardiovascular events, including heart attack, stroke, and death, compared to those who continued the medication. Even a temporary hiatus of at least six months in dosing resulted in a reduced cardiovascular risk reduction (12%) compared to consistent treatment (18%). The study highlights a 'metabolic yo-yo' effect, where the benefits of the drug diminish quickly upon cessation, leading to a worsening of blood pressure, chol...
TrendlineTrendline
Novo Nordisk Licenses Nanexa's PharmaShell Technology for Long-Acting GLP-1 Treatments

Novo Nordisk Licenses Nanexa's PharmaShell Technology for Long-Acting GLP-1 Treatments

Novo Nordisk Licenses Nanexa's PharmaShell Technology for Long-Acting GLP-1 Treatments
TrendlineTrendline
Dylan Dreyer Inquires About Craig Melvin's Potential GLP-1 Use on 'Today' Show

Dylan Dreyer Inquires About Craig Melvin's Potential GLP-1 Use on 'Today' Show

Dylan Dreyer Inquires About Craig Melvin's Potential GLP-1 Use on 'Today' Show
Rapid ReadRapid Read
3,4,6-Tri-O-galloyl-D-glucose Identified as Potential Inhibitor for Diabetes Research

3,4,6-Tri-O-galloyl-D-glucose Identified as Potential Inhibitor for Diabetes Research

A compound named 3,4,6-Tri-O-galloyl-D-glucose (also known as 3,4,6-Trigalloylglucose) has been identified as an inhibitor of α-amylase and α-glucosidase enzymes. This compound exhibits mixed-type inhibition properties against these enzymes. Specifically, it shows an IC50 of 334.6 µM and a Ki of 307.5 µM for porcine α-amylase, and an IC50 of 46.5 µM and a Ki of 39.9 µM for yeast α-glucosidase. Beyond its enzymatic inhibition, 3,4,6-Tri-O-galloyl-D-glucose also demonstrates free radical scavenging ability, ferric-reducing power, and antioxidant activity. These characteristics suggest its potential utility in the research of diabetes, particularly type 1 diabetes, and glucose metabolism. The compound has a molecular formula of C27H24O18, a molecular weight of 636.47, and a purity of 99.98%.
TheStreetTheStreet
Medicare just handed Eli Lilly a massive weight-loss win

Medicare just handed Eli Lilly a massive weight-loss win

As Medicare Bridge participation surges, Novo Nordisk's share of those new patients is drawing attention.
Rapid ReadRapid Read
Weight-Loss Medications Linked to Nutritional Deficiencies in Children and Teens, Study Finds

Weight-Loss Medications Linked to Nutritional Deficiencies in Children and Teens, Study Finds

A new study published in the journal Childhood Obesity indicates that weight-loss drugs like Ozempic and Zepbound, while powerful tools against childhood obesity, are not without risks. The research found that approximately 1 in 6 children prescribed a GLP-1 medication were diagnosed with a nutritional deficiency within a year of starting treatment. Vitamin D deficiency was the most common, affecting over 12% of children, followed by anemia (nutritional and iron-deficiency). Researchers analyzed insurance claims data from 2017 to 2022 for over 2,000 children aged 10 to 17 who received a GLP-1 drug. The average age of these children was 15, with nearly 63% diagnosed with obesity. Senior author Justin Ryder, vice chair of research at Ann & Robert H. Lurie Children’s Hospital of Chicago, emphasized the importance of proactive nutritional management, noting that only 5% of patients received nutritional counseling within 30 days of GLP-1 treatment, and less than 25% within six months.
TrendlineTrendline
Ozempic Linked to Infertility Reversal and Multiple Pregnancies for California Nurse

Ozempic Linked to Infertility Reversal and Multiple Pregnancies for California Nurse

Ozempic Linked to Infertility Reversal and Multiple Pregnancies for California Nurse
TheStreetTheStreet
91-year-old investor sees healthcare titan doubling in 3 years

91-year-old investor sees healthcare titan doubling in 3 years

The billionaire Home Depot co-founder has held the stock since 1977. Here's where he thinks it's going.
Rapid ReadRapid Read
Doctors Warn of Vision Loss Risk Linked to Popular Weight-Loss Drugs

Doctors Warn of Vision Loss Risk Linked to Popular Weight-Loss Drugs

Multiple lawsuits have been filed in the past year concerning a condition called non-arteritic anterior ischemic optic neuropathy (NAION), which causes rapid-onset vision changes and potential blindness, reportedly linked to popular weight-loss drugs. Dr. Elizabeth Steele of the UAB Department of Optometry explains that NAION involves a blood pressure issue at the optic nerve, a structure vital for connecting the eye to the brain and requiring proper blood flow and pressure. This condition typically affects aging adults with pre-existing conditions such as high blood pressure, obesity, diabetes, and high cholesterol, which are often the same patient demographics prescribed these weight-loss medications. Additionally, GLP-1 drugs, particularly semaglutide, are being investigated for a second potential link to vision loss. For patients with severe diabetes, rapid blood sugar control and significant weight loss in the initial months of taking the drug can compromise the vascular system in the retina, increasi...
Rapid ReadRapid Read
GLP-1 Drug Users Face Increased Regurgitation Risk During Surgery, Study Finds

GLP-1 Drug Users Face Increased Regurgitation Risk During Surgery, Study Finds

A recent study presented at the annual meeting of the Association of Anaesthetists of Great Britain and Ireland indicates that patients taking GLP-1 medications, such as Ozempic and Wegovy, may face an increased risk of regurgitation during or after surgery. These drugs, which are popular for weight loss and diabetes management, slow down digestion, meaning food can remain in the stomach longer than usual. The study, which examined the medical records of 47,039 adults undergoing procedures in the UK, found that GLP-1 users were approximately 11 times more likely to experience regurgitation compared to non-users. While most cases occurred as patients woke from anesthesia, some happened during surgery. Critically, two cases progressed to aspiration, where stomach contents are inhaled into the lungs, a potentially dangerous complication that can lead to severe lung damage, breathing problems, and even respiratory failure. The researchers noted that nearly one-third of GLP-1 users in the study had been advised...
Rapid ReadRapid Read
Svetlana Mojsov Named Citation Laureate for GLP-1 Research

Svetlana Mojsov Named Citation Laureate for GLP-1 Research

Svetlana Mojsov, the Lulu Chow Wang and Robin Chemers Neustein Research Professor at Rockefeller University, has been designated a 2026 Citation Laureate by Clarivate. This recognition is for her pivotal research on peptide synthesis, which led to the identification and characterization of glucagon-like peptide-1 (GLP-1) and studies of its biological activity. Her work was instrumental in the development of a new class of drugs used to treat diabetes and obesity. Mojsov shares this honor with Daniel J. Drucker of the University of Toronto and Jens Juul Holst of the University of Copenhagen. Clarivate's Citation Laureate program identifies scientists whose work is among the top 0.02 percent most widely cited, making them highly likely candidates for Nobel Prizes. Since its inception in 1989, 89 Citation Laureates have gone on to win Nobel Prizes.